Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2022–2026

RepliFate · DNA replication at the heart of cell fate decisions and cancer development

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2022-10-01 → 2026-09-30
Финансиране от ЕС
2 650 313 €
Участници
21
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Репликацията на ДНК се изследва като фактор, който определя идентичността на клетката и нейния отговор при стрес. Разбирането на тези механизми помага за разработването на нови методи за лечение на рака и подобряване на здравето.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

DNA replication at the heart of cell fate decisions and cancer development

RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity. RepliFate investigates the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent the development of cancer. We shift the paradigm in the field to place DNA replication at the center stage as the driver of cell identity and not a mere bystander. This approach paves the way for the development of innovative treatments by exploring the links between DNA replication and cell fate, the immune response and cancer. Thus, RepliFate contributes to the promotion of health and well-being in the European society. In particular we tackle Mission Cancer set on the Horizon Europe by contributing to the objectives Understand and Optimise in Mission Cancer. RepliFate is a meeting point of academia, industry and society to promote research in the field of DNA replication in health and disease. RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. We have created an outstanding training program to foster independent and out-of-the-box views in the fellows to train them as the future leaders in the field. RepliFate bridges basic and applied science to improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity. RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation.RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз